This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Santarus, Inc.. Active years: 2018-2020.
Company Filing History:
Years Active: 2018-2020
Title: The Innovations of Stephen Paul Levine
Introduction
Stephen Paul Levine is a notable inventor based in Norristown, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled-release solid dosage forms of mesalamine. With a total of two patents to his name, Levine's work has had a meaningful impact on the treatment of inflammatory bowel diseases.
Latest Patents
Levine's latest patents focus on controlled-release solid dosage forms of mesalamine. These inventions describe capsules that comprise a plurality of coated mini-tablets. One aspect of his invention relates to methods of treating patients suffering from inflammatory bowel disease. This includes administering a therapeutically effective amount of the solid dosage form to the patient. Additionally, his inventions address methods for inducing and maintaining remission of inflammatory bowel disease, specifically targeting conditions such as ulcerative colitis and Crohn's disease.
Career Highlights
Stephen Paul Levine is associated with Santarus, Inc., where he has been instrumental in advancing pharmaceutical innovations. His work has contributed to the development of effective treatments for patients with challenging gastrointestinal conditions. Levine's expertise in controlled-release formulations has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Levine has collaborated with notable colleagues, including Craig Michael Bowe and John Carter. These partnerships have fostered an environment of innovation and have led to the successful development of new therapeutic solutions.
Conclusion
Stephen Paul Levine's contributions to the field of pharmaceuticals, particularly through his patents on mesalamine formulations, highlight his role as an influential inventor. His work continues to benefit patients suffering from inflammatory bowel diseases, showcasing the importance of innovation in healthcare.